BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 26170847)

  • 1. Clinicopathologic characteristics and prognostic factors for HER2-positive patients with metastatic breast cancer in southern China.
    Qin T; Yuan ZY; Peng RJ; Bai B; Zeng YD; Shi YX; Teng XY; Liu DG; Wang SS
    Arch Med Sci; 2015 Jun; 11(3):544-50. PubMed ID: 26170847
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factors influencing survival among patients with HER2-positive metastatic breast cancer treated with trastuzumab.
    Blanchette PS; Desautels DN; Pond GR; Bartlett JMS; Nofech-Mozes S; Yaffe MJ; Pritchard KI
    Breast Cancer Res Treat; 2018 Jul; 170(1):169-177. PubMed ID: 29520532
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinicopathological and Treatment-Associated Prognostic Factors in Patients with Breast Cancer Leptomeningeal Metastases in Relation to Tumor Biology.
    Griguolo G; Pouderoux S; Dieci MV; Jacot W; Bourgier C; Miglietta F; Firmin N; Conte P; Viala M; Guarneri V; Darlix A
    Oncologist; 2018 Nov; 23(11):1289-1299. PubMed ID: 30120164
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exploring prognostic factors for HER2-positive metastatic breast cancer: a retrospective cohort study in a major Swiss hospital.
    Bringolf L; Pestalozzi B; Fink D; Dedes K
    Swiss Med Wkly; 2016; 146():w14393. PubMed ID: 28102883
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognosis of metastatic breast cancer subtypes: the hormone receptor/HER2-positive subtype is associated with the most favorable outcome.
    Lobbezoo DJ; van Kampen RJ; Voogd AC; Dercksen MW; van den Berkmortel F; Smilde TJ; van de Wouw AJ; Peters FP; van Riel JM; Peters NA; de Boer M; Borm GF; Tjan-Heijnen VC
    Breast Cancer Res Treat; 2013 Oct; 141(3):507-14. PubMed ID: 24104881
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hormone receptor status predicts the clinical outcome of human epidermal growth factor 2-positive metastatic breast cancer patients receiving trastuzumab therapy: a multicenter retrospective study.
    Wang Y; Sun T; Wan D; Sheng L; Li W; Zhu H; Li Y; Lu J
    Onco Targets Ther; 2015; 8():3337-48. PubMed ID: 26648738
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
    Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
    Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis.
    Gao JJ; Cheng J; Bloomquist E; Sanchez J; Wedam SB; Singh H; Amiri-Kordestani L; Ibrahim A; Sridhara R; Goldberg KB; Theoret MR; Kluetz PG; Blumenthal GM; Pazdur R; Beaver JA; Prowell TM
    Lancet Oncol; 2020 Feb; 21(2):250-260. PubMed ID: 31859246
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epidemiological characteristics, clinical outcomes and management patterns of metastatic breast cancer patients in routine clinical care settings of Greece: Results from the EMERGE multicenter retrospective chart review study.
    Kotsakis A; Ardavanis A; Koumakis G; Samantas E; Psyrri A; Papadimitriou C
    BMC Cancer; 2019 Jan; 19(1):88. PubMed ID: 30658600
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Capecitabine after anthracycline and taxane exposure in HER2-negative metastatic breast cancer patients: response, survival and prognostic factors.
    Gilabert M; Bertucci F; Esterni B; Madroszyk A; Tarpin C; Jacquemier J; Extra JM; Viens P; Gonçalves A
    Anticancer Res; 2011 Mar; 31(3):1079-86. PubMed ID: 21498742
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characteristics and Prognostic Factors for Patients With HER2-overexpressing Breast Cancer and Brain Metastases in the Era of HER2-targeted Therapy: An Argument for Earlier Detection.
    Morikawa A; Wang R; Patil S; Diab A; Yang J; Hudis CA; McArthur HL; Beal K; Seidman AD
    Clin Breast Cancer; 2018 Oct; 18(5):353-361. PubMed ID: 29337140
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial.
    Park YH; Kim TY; Kim GM; Kang SY; Park IH; Kim JH; Lee KE; Ahn HK; Lee MH; Kim HJ; Kim HJ; Lee JI; Koh SJ; Kim JY; Lee KH; Sohn J; Kim SB; Ahn JS; Im YH; Jung KH; Im SA;
    Lancet Oncol; 2019 Dec; 20(12):1750-1759. PubMed ID: 31668850
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characteristics and Outcomes of Patients With Breast Cancer With Leptomeningeal Metastasis.
    Morikawa A; Jordan L; Rozner R; Patil S; Boire A; Pentsova E; Seidman AD
    Clin Breast Cancer; 2017 Feb; 17(1):23-28. PubMed ID: 27569275
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the Predictive and Prognostic Values of Stromal Tumor-Infiltrating Lymphocytes in HER2-Positive Breast Cancers treated with neoadjuvant chemotherapy.
    Yang X; Rao J; Yang W; Shui R
    Target Oncol; 2018 Dec; 13(6):757-767. PubMed ID: 30406444
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic Factors in HER2-Positive Primary Breast Cancer Patients Treated Using Neoadjuvant Chemotherapy Plus Trastuzumab.
    Fujita N; Enomoto Y; Inakami K; Yanagisawa T; Iguchi C; Aono T; Nomura T; Yamamoto H; Kasugai T; Shiba E
    Oncology; 2020; 98(1):35-41. PubMed ID: 31574500
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of clinicopathological features and prognostic factors of breast cancer brain metastasis.
    Chen YR; Xu ZX; Jiang LX; Dong ZW; Yu PF; Zhang Z; Gu GL
    World J Clin Oncol; 2023 Nov; 14(11):445-458. PubMed ID: 38059189
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trastuzumab and survival of patients with metastatic breast cancer.
    Kast K; Schoffer O; Link T; Forberger A; Petzold A; Niedostatek A; Werner C; Klug SJ; Werner A; Gatzweiler A; Richter B; Baretton G; Wimberger P
    Arch Gynecol Obstet; 2017 Aug; 296(2):303-312. PubMed ID: 28616827
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of hormone therapy on long-term outcomes of patients with human epidermal growth factor receptor 2- and hormone receptor-positive metastatic breast cancer: real world experience in China.
    Du F; Yuan P; Wang JY; Ma F; Fan Y; Luo Y; Xu BH
    Asian Pac J Cancer Prev; 2015; 16(3):903-7. PubMed ID: 25735380
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic and clinical impact of the endocrine resistance/sensitivity classification according to international consensus guidelines for advanced breast cancer: an individual patient-level analysis from the Mammella InterGruppo (MIG) and Gruppo Italiano Mammella (GIM) studies.
    Lambertini M; Blondeaux E; Bisagni G; Mura S; De Placido S; De Laurentiis M; Fabi A; Rimanti A; Michelotti A; Mansutti M; Russo A; Montemurro F; Frassoldati A; Durando A; Gori S; Turletti A; Tamberi S; Urracci Y; Fregatti P; Razeti MG; Caputo R; De Angelis C; Sanna V; Gasparini E; Agostinetto E; de Azambuja E; Poggio F; Boni L; Del Mastro L
    EClinicalMedicine; 2023 May; 59():101931. PubMed ID: 37256095
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Breast cancer patients with brain metastases or leptomeningeal disease: 10-year results of a national cohort with validation of prognostic indexes.
    Znidaric T; Gugic J; Marinko T; Gojkovic Horvat A; Paulin Kosir MS; Golo D; Ivanetic Pantar M; Ratosa I
    Breast J; 2019 Nov; 25(6):1117-1125. PubMed ID: 31286623
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.